2013-09-18 09:16:10 - New Pharmaceuticals market report from GlobalData: "EpiCast Report: Acne - Epidemiology Forecast to 2022"
Acne vulgaris (acne) is an inflammatory skin disease that affects nearly all adolescents and adults at some point in their lives. The clinical presentation of acne ranges from a mild comedonal form to severe inflammatory cystic acne of the face, chest, and back. Globally, acne has a lifetime prevalence of over 90% in people of all ages, and a point-prevalence of approximately 85% in the population ages 15-24 years.
GlobalData's epidemiological analysis forecasts an increase in the total prevalent cases of acne in people ages 10-44 years in the six major markets (6MM) (US, France, Germany, Italy, Spain, and UK), from 103.91 million prevalent cases in 2012 to 105.46 million prevalent cases in 2022, with a decadal growth rate of 1.5%.
As GlobalData epidemiologists used steady prevalence proportions of acne over the forecast period, the growth in prevalent cases in each market can be attributed to the change in population demographics in people ages 10-44 years in the respective markets.
Full Report Details at
- www.fastmr.com/prod/685005_epicast_report_acne_epidemiology_fore ..
Although acne is not a life-endangering condition, it is associated with a huge psychosocial impact and economic burden. GlobalData's epidemiological forecast emphasizes the need for preventive measures that are directed towards high-risk groups and signifies the need for early intervention with the available effective treatments in order to tackle the increasing burden of acne.
GlobalData epidemiologists forecast the prevalent cases of acne in the 6MM from 2012-2022 using nationally-representative, country-specific studies published in peer-reviewed journals that provided the age- and sex-specific prevalence of acne in the 6MM. Additionally, they further segmented the total prevalent cases of acne by severity. GlobalData epidemiologists ensured that the forecast methodology was consistent across all the 6MM to allow for a meaningful comparison of the total prevalent cases of acne across these markets.
* The Acne EpiCast Report provides an overview of the risk factors and global trends of acne in the 6MM (US, France, Germany, Italy, Spain, and UK). It includes a 10-year epidemiology forecast of acne prevalent cases segmented by age (in five-year increments beginning at age 0 and ending at age 44 years), sex, and stage in these six markets.
* The acne epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
* The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 6MM.
Reasons to Get this Report
* Develop business strategies by understanding the trends shaping and driving the global acne market.
* Quantify patient populations in the global acne market to improve product design, pricing, and launch plans.
* Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for acne therapeutics in each of the markets covered.
* Identify the percentage of acne prevalent cases by stage.
Partial Table of Contents:
1 Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
3.1 Disease Background
3.2 Risk Factors and Comorbidities
3.2.1 A family history of acne increases the risk of acne by four times
3.2.2 Diet is the most common aggravating factor of acne
3.2.3 The relationship between smoking and acne is unclear
3.2.4 Depression and anxiety are common comorbidities in acne patients
3.3 Global Trends
3.4 Forecast Methodology
3.4.1 Sources Used
3.4.2 Sources Not Used
3.5 Forecast Assumptions and Methods
3.5.4 Italy and Spain
3.6 Epidemiology Forecast for Acne (2012-2022)
3.6.1 Total Prevalent Cases of Acne Vulgaris
3.6.2 Age-Specific Total Prevalent Cases of Acne Vulgaris
3.6.3 Sex-Specific Total Prevalent Cases of Acne Vulgaris
3.6.4 Age-Standardized Total Prevalence of Acne Vulgaris
3.6.5 Total Prevalent Cases of Acne Vulgaris by Severity
3.7.1 Conclusions on Epidemiological Trends
3.7.2 Limitations of the Analysis
3.7.3 Strengths of the Analysis
4.2 About the Authors
4.2.3 Global Director of Epidemiology and Health Policy
4.2.4 Global Head of Healthcare
4.3 About GlobalData
4.4 About EpiCast
List of Tables
1.1 List of Tables
Table 1: Risk Factors and Comorbidities for Acne
Table 2: Classification of Acne Severity
Table 3: 6MM, Sources of Acne Prevalence Data
Table 4: 6MM, Sources of Acne Severity Data
Table 5: 6MM, Total Prevalent Cases of Acne Vulgaris, Ages 10-44 years, Both Sexes, N (Millions), 2012-2022
Table 6: 6MM, Total Prevalent Cases of Acne Vulgaris, by Age, Both Sexes, N (Millions), (Row %), 2012
Table 7: 6MM, Total Prevalent Cases of Acne Vulgaris, by Sex, Ages 10-44 Years, N (Row %), 2012
Table 8: 6MM, Total Prevalent Cases of Acne Vulgaris by Severity, Ages 10-44 Years, Both Sexes, N (Millions) (Row %), 2012
List of Figures
1.2 List of Figures
Figure 1: 6MM, Total Prevalent Cases of Acne Vulgaris, Ages 10-44 years, Both Sexes, N (Millions), 2012-2022
Full Table of Contents is available at:
GlobalData is a leading provider of global business intelligence including market, competitor, product and customer information. It provides in-depth research, analysis, data and forecasts through a range of interactive online databases, reports and management briefings. GlobalData has a large team of experienced research and analysis, consulting, and marketing experts. It has a global presence, including key offices in the US, Europe and Asia. The group has over 50 years of experience of delivering market intelligence data and analysis and a highly experienced senior management team. View more research from GlobalData at www.fastmr.com/catalog/publishers.aspx?pubid=1015
About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.
For more information about these or related research reports, please visit our website at www.fastmr.com
or call us at 1.800.844.8156.